Newron Sweden AB

Ad hoc announcement pursuant to Art. 53 LR Further study analysis reveals significant multi-domain benefits in PANSS and Clinical Global Impression of Change (CGI-C) ratings Benefit on efficacy measures increased over time, suggesting larger and enduring patient effects to be expected during long-term treatment MILAN--(BUSINESS WIRE)-- Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system (CNS), presents additional results from the international, randomized, double-blind, placebo-controlled study 008A that evaluated the efficacy and safety of evenamide (30 mg bid) as add-on treatment in 291 patients not benefitting from their second-generation antipsychotic medication, including clozapine. Initial top line data announced on 30th April 2024 demonstrated that the study met its primary endpoint, an improvement of the Positive and Negative Syndrome Scale (PANSS) Total Score as well as the key secondary endpoint, an improvement of the Clinical Global Impression of Severity (CGI-S), in the a-priori defined regulatory analysis. Additional analyses for the secondary endpoints indicate significant effects achieved at the endpoint (Day 29), on all the following measures: - PANSS total: Proportion of patients with a clinically relevant improvement (more than 20% improvement from baseline); p-value < 0.05; - Clinical Global Impression of Change (CGI-C): Mean rating at endpoint; evenamide 3.3 versus placebo 3.5; p-value < 0.001; - Clinical Global Impression of Change (CGI-C): Proportion of patients rated as showing any improvement; p-value < 0.05; - Clinical Global Impression of Change (CGI-C): Proportion of patients rated as at least “much improved”; evenamide: 31.3% versus placebo: 17.3%; p-value = 0.006; - PANSS Positive subscale: Mean change from baseline; p-value < 0.05; - PANSS Negative subscale: Mean change from baseline; p-value < 0.05. The sensitivity analyses for the PANSS total (primary endpoint) and CGI-S (secondary endpoint) confirmed a statistically significant improvement for evenamide irrespective of the population analyzed and the statistical methods used; some examples are provided below: - PANSS total worst observation carried forward (WOCF) ANCOVA p-value = 0.008; - PANSS total Multiple Imputation (MI) ANCOVA: p-value = 0.006; - CGI-S Multiple Imputation (MI) ANCOVA: p-value = 0.014. In the study, the addition of 30 mg (bid) of evenamide to the patients’ current antipsychotic medication was very well tolerated, with a similar pro placebo with no increases in EPS, weight gain, blood glucose, metabolic syndrome, sexual dysfunction, CNS or cardiac effects, or laboratory abnormalities. Study 008A is the first well-designed study demonstrating efficacy of an adjunctive treatment in benefiting patients who do not respond to their current antipsychotic. Evenamide also is the first glutamate modulator to demonstrate efficacy in inadequately responding patients with schizophrenia in a placebo-controlled study. Ravi Anand, MD, Chief Medical Officer of Newron, stated: “These new efficacy results from study 008A attest to the clinical relevance of the benefits for patients, based on the primary and key secondary endpoints. The results for the CGI-C rated by an experienced psychiatrist who assesses not only the symptoms of psychosis, but also the impact of treatment on social interactions, insight, and functioning, indicated a significant proportion of evenamide patients were considered as at least ‘much improved’. Significant improvement was also noted on both positive and negative symptoms of schizophrenia. Most importantly, the benefits noted on the efficacy measures increased up to Day 29, thus suggesting larger and enduring effects during longer term treatment. These findings, along with those noted in study 014/015, where patients with treatment resistant schizophrenia treated with evenamide for 1-year experienced progressive, sustained and long-lasting clinically significant important benefits, further highlight the growing importance of glutamate modulation for the development of novel treatments for patients with schizophrenia.” About evenamide Evenamide, an orally available new chemical entity, specifically blocks voltage-gated sodium channels (VGSCs) and is devoid of biological activity at >130 other CNS targets. It normalizes glutamate release induced by aberrant sodium channel activity (veratridine-stimulated), without affecting basal glutamate levels, due to inhibition of VGSCs. Combinations of ineffective doses of evenamide and other APs, including clozapine, were associated with benefit in animal models of psychosis, suggesting synergies in mechanisms that may provide benefit in patients who are poor responders to current APs, including clozapine. About Newron Pharmaceuticals Newron (SIX: NWRN, XETRA: NP5) is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system. The Company is headquartered in Bresso near Milan, Italy. Xadago®/safinamide has received marketing authorization for the treatment of Parkinson’s disease in the European Union, Switzerland, the UK, the USA, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan and South Korea, and is commercialized by Newron’s Partner Zambon. Supernus Pharmaceuticals holds the commercialization rights in the USA. Meiji Seika has the rights to develop and commercialize the compound in Japan and other key Asian territories. Newron is also developing evenamide as the potential first add-on therapy for the treatment of patients with symptoms of schizophrenia. For more information, please visit: Important Notices This document contains forward-looking statements, including (without limitation) about (1) Newron’s ability to develop and expand its business, successfully complete development of its current product candidates, the timing of commencement of various clinical trials and receipt of data and current and future collaborations for the development and commercialization of its product candidates, (2) the market for drugs to treat CNS diseases and pain conditions, (3) Newron’s financial resources, and (4) assumptions underlying any such statements. In some cases, these statements and assumptions can be identified by the fact that they use words such as “will”, “anticipate”, “estimate”, “expect”, “project”, “intend”, “plan”, “believe”, “target”, and other words and terms of similar meaning. All statements, other than historical facts, contained herein regarding Newron's strategy, goals, plans, future financial position, projected revenues and costs and prospects are forward-looking statements. By their very nature, such statements and assumptions involve inherent risks and uncertainties, both general and specific, and risks exist that predictions, forecasts, projections and other outcomes described, assumed or implied therein will not be achieved. Future events and actual results could differ materially from those set out in, contemplated by or underlying the forward-looking statements due to a number of important factors. These factors include (without limitation) (1) uncertainties in the discovery, development or marketing of products, including without limitation difficulties in enrolling clinical trials, negative results of clinical trials or research projects or unexpected side effects, (2) delay or inability in obtaining regulatory approvals or bringing products to market, (3) future market acceptance of products, (4) loss of or inability to obtain adequate protection for intellectual property rights, (5) inability to raise additional funds, (6) success of existing and entry into future collaborations and licensing agreements, (7) litigation, (8) loss of key executive or other employees, (9) adverse publicity and news coverage, and (10) competition, regulatory, legislative and judicial developments or changes in market and/or overall economic conditions. Newron may not actually achieve the plans, intentions or expectations disclosed in forward-looking statements and assumptions underlying any such statements may prove wrong. Investors should therefore not place undue reliance on them. There can be no assurance that actual results of Newron's research programs, development activities, commercialization plans, collaborations and operations will not differ materially from the expectations set out in such forward-looking statements or underlying assumptions. Newron does not undertake any obligation to publicly update or revise forward-looking statements except as may be required by applicable regulations of the SIX Swiss Exchange or the Dusseldorf Stock Exchange where the shares of Newron are listed. This document does not contain or constitute an offer or invitation to purchase or subscribe for any securities of Newron and no part of it shall form the basis of or be relied upon in connection with any contract or commitment whatsoever. View source version on businesswire.com: Contacts For more information: Newron Stefan Weber – CEO +39 02 6103 46 26 pr@newron.com UK/Europe Simon Conway / Ciara Martin / Natalie Garland-Collins, FTI Consulting +44 20 3727 1000 SCnewron@fticonsulting.com Switzerland Valentin Handschin, IRF +41 43 244 81 54 handschin@irf-reputation.ch Germany/Europe Anne Hennecke / Caroline Bergmann, MC Services +49 211 52925222 newron@mc-services.eu USA Paul Sagan, LaVoieHealthScience +1 617 374 8800, Ext. 112 psagan@lavoiehealthscience.com Source: Newron Pharmaceuticals S.p.A. View this news release online at:

Italian biotech Newron Pharmaceuticals is trying to bring forward the first schizophrenia treatment in decades with evenamide, which could be combined with standard of care like clozapine for patients with chronic disease who do not respond to other treatments. Newron Pharmaceuticals’ add-on schizophrenia treatment improved both positive and negative symptoms as well as severity in patients with the disorder during a phase 2/3 study. The Italian biotech is trying to bring forward the first schizophrenia treatment in decades with evenamide, which could be combined with standard of care like clozapine for patients with chronic disease who do not respond to other treatments. The trial met the main goal of showing improvement on a scale of positive and negative schizophrenia symptoms called the Positive and Negative Syndrome Scale (PANSS), according to a Tuesday release. Positive symptoms include delusions, hallucinations, excitement and grandiosity, while negative symptoms are emotional and social withdrawal, difficulty in abstract thinking and blunted affect. Patients who took evenamide also saw an improvement in the severity of their condition, which was a key secondary endpoint. The four-week Study 008A was conducted at 45 centers in 11 countries, with 291 patients receiving either the study drug or placebo in addition to their current antipsychotic therapy. Three patients discontinued due to adverse events, including two who were on evenamide and one on placebo who died during the trial. Overall, there were no safety flags discovered during the trial and no difference between the rate of central nervous system, gastrointestinal or other adverse events in the evenamide or placebo groups. Newron called the main endpoint results “highly statistically significant,” with patients on evenamide seeing a 10.2-point reduction on the PANSS scale at Day 29, compared to 7.6 for the placebo group. Shares of Newron rose 11% on the Swiss markets to 8.50 Swiss francs ($9.29), compared to 7.64 Swiss francs ($8.35), as of 2:59 p.m. CEST (8:59 a.m. ET). Last year, Newron reported that the effect of evenamide increased between six months and one year. After one year, the biotech reported a more than 50% increase in the six-week change on the PANSS symptom scale. A 30% change was seen after six months. Newron plans to disclose more from the study in the coming weeks. The company also hopes to use the data to make the case for a "potentially pivotal" phase 3 trial testing evenamide over one year in patients with treatment-resistant schizophrenia. 

Plus, news about Newron and SynOx: Daré Bioscience inks royalty deal with XOMA: The company received $22 million, which is expected to help progress a pair of women’s health therapies through Phase 3. Dare’s stock $DARE was up about 28% after announcing the agreement. — Jaimy Lee Qlaris Bio secures $24M in Series B: The proceeds will support the continued development of the biotech’s Phase 2 asset, QLS‑111, which is designed to lower intraocular pressure in patients with open-angle glaucoma and ocular hypertension. The fundraise was co-led by Canaan and New Leaf Venture Partners. — Ayisha Sharma You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.